{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:15:40Z","timestamp":1773306940563,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R01AG042178, R01AG47812, R01NS105473, and AG060767"],"award-info":[{"award-number":["R01AG042178, R01AG47812, R01NS105473, and AG060767"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12035-020-02022-0","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T06:15:35Z","timestamp":1594793735000},"page":"4106-4116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics"],"prefix":"10.1007","volume":"57","author":[{"given":"Ramesh","family":"Kandimalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albin","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrika","family":"Abburi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayalakshmi","family":"Vallamkondu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-9948","authenticated-orcid":false,"given":"P. Hemachandra","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2022_CR1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"key":"2022_CR2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2468-1253(20)30080-7","volume":"5","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Pan H, She Q, Wang F, Chen M (2020) Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis. Lancet Gastroenterol Hepatol 5:528\u2013529","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1824","key":"2022_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 323(1824):1836. https:\/\/doi.org\/10.1001\/jama.2020.6019","journal-title":"JAMA."},{"issue":"325","key":"2022_CR4","first-page":"328","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu A, Peng Y, Huang B et al (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27(325):328","journal-title":"Cell Host Microbe"},{"key":"2022_CR5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med 26:450\u2013452","journal-title":"Nat Med"},{"key":"2022_CR6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/348600a0","volume":"348","author":"V Lotteau","year":"1990","unstructured":"Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA (1990) Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348:600\u2013605","journal-title":"Nature"},{"key":"2022_CR7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","volume":"19","author":"SF Wu","year":"2017","unstructured":"Wu SF, Chang CB, Hsu JM, Lu MC, Lai NS, Li C, Tung CH (2017) Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther 19:183","journal-title":"Arthritis Res Ther"},{"key":"2022_CR8","first-page":"55","volume":"24","author":"BE van den Borne","year":"1997","unstructured":"van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL (1997) Chloroquineand hydroxychloroquine equally affect tumor necrosis factor-alpha interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 24:55\u201360","journal-title":"J Rheumatol"},{"key":"2022_CR9","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol (Baltimore, Md : 1950) 186:4794\u20134804","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"key":"2022_CR10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nature07405","volume":"456","author":"SE Ewald","year":"2008","unstructured":"Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, Barton GM (2008) The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456:658\u2013662","journal-title":"Nature"},{"key":"2022_CR11","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1093\/emboj\/17.21.6230","volume":"17","author":"H H\u00e4cker","year":"1998","unstructured":"H\u00e4cker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB et al (1998) CpG-DNA-specific activation of antigen presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 17:6230\u20136240","journal-title":"EMBO J"},{"key":"2022_CR12","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.20051696","volume":"202","author":"J Vollmer","year":"2005","unstructured":"Vollmer J, Tluk S, Schmitz C et al (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202:1575\u20131585","journal-title":"J Exp Med"},{"key":"2022_CR13","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","volume":"194","author":"J An","year":"2015","unstructured":"An J, Woodward JJ, Sasaki T, Minie M, Elkon KB (2015) Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase DNA interaction. J Immunol (Baltimore, Md : 1950) 194:4089\u20134093","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"key":"2022_CR14","doi-asserted-by":"publisher","unstructured":"Zhou D, Dai SM, Tong Q (2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. The Journal of antimicrobial chemotherapy. J Antimicrob Chemother:dkaa114. https:\/\/doi.org\/10.1093\/jac\/dkaa114","DOI":"10.1093\/jac\/dkaa114"},{"key":"2022_CR15","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55","author":"CA Devaux","year":"2020","unstructured":"Devaux CA, Rolain JM, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 55:105938","journal-title":"Int J Antimicrob Agents"},{"key":"2022_CR16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72\u201373","journal-title":"Biosci Trends"},{"key":"2022_CR17","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"2022_CR18","first-page":"215","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen J, Liu D, Liu L et al (2020) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang da xue xue bao Yi xue ban = J Zhejiang Univ Med Sci 49:215\u2013219","journal-title":"Zhejiang da xue xue bao Yi xue ban = J Zhejiang Univ Med Sci"},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"m1335","DOI":"10.1136\/bmj.m1335","volume":"369","author":"J Lenzer","year":"2020","unstructured":"Lenzer J (2020) Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 369:m1335 Published 2020. https:\/\/doi.org\/10.1136\/bmj.m1335","journal-title":"BMJ"},{"key":"2022_CR20","doi-asserted-by":"publisher","unstructured":"Yi SG, Rogers AW, Saharia A, et al Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center [published online ahead of print, 2020 Jun 1]. Transplantation. 2020; https:\/\/doi.org\/10.1097\/TP.0000000000003339","DOI":"10.1097\/TP.0000000000003339"},{"key":"2022_CR21","doi-asserted-by":"publisher","unstructured":"Yao X, Ye F, Zhang M, et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [published online ahead of print, 2020 Mar 9]. Clin Infect Dis. ciaa237. https:\/\/doi.org\/10.1093\/cid\/ciaa237","DOI":"10.1093\/cid\/ciaa237"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/jama.2020.4742","volume":"323","author":"AC Kalil","year":"2020","unstructured":"Kalil AC (2020) Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 323:1897. https:\/\/doi.org\/10.1001\/jama.2020.4742","journal-title":"JAMA"},{"key":"2022_CR23","unstructured":"Interview with David Juurlink (2020) Coronavirus (COVID-19) update: chloroquine\/hydroxychloroquine and azithromycin. JAMA March 24, 2020. Accessed 5 Apr 2020. https:\/\/edhub.ama-assn.org\/jn-learning\/audioplayer\/18337225"},{"key":"2022_CR24","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.3899\/jrheum.110686","volume":"38","author":"A Osadchy","year":"2011","unstructured":"Osadchy A, Ratnapalan T, Koren G (2011) Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 38:2504\u20132508","journal-title":"J Rheumatol"},{"key":"2022_CR25","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mour\u00e3o MPG, Brito-Sousa JD et al (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3:e208857","journal-title":"JAMA Netw Open"},{"key":"2022_CR26","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3:e343","journal-title":"PLoS Med"},{"key":"2022_CR27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL et al (2004) Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252\u2013256","journal-title":"Thorax"},{"key":"2022_CR28","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J et al (2014) Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875\u20134884","journal-title":"Antimicrob Agents Chemother"},{"key":"2022_CR29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","volume":"92","author":"TT Yao","year":"2020","unstructured":"Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option. J Med Virol 92:556\u2013563","journal-title":"J Med Virol"},{"key":"2022_CR30","first-page":"399","volume":"9","author":"KS Chan","year":"2003","unstructured":"Chan KS, Lai ST, Chu CM et al (2003) Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Medical Journal = Xianggang yi xue za zhi 9:399\u2013406","journal-title":"Hong Kong Medical Journal = Xianggang yi xue za zhi"},{"key":"2022_CR31","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799","journal-title":"N Engl J Med"},{"key":"2022_CR32","doi-asserted-by":"crossref","unstructured":"De Meyer S, Bojkova D, Cinati J, et al (2020) Lack of antiviral activity of darunavir against SARS-CoV-2. medRxiv 2020: 2020.04.03.20052548","DOI":"10.1101\/2020.04.03.20052548"},{"key":"2022_CR33","unstructured":"https:\/\/www.who.int\/blueprint\/priority-diseases\/key action\/Table_of_therapeutics_Appendix_17022020.pdf (accessed on 28 May 2020)"},{"key":"2022_CR34","first-page":"26971","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:26971","journal-title":"Cell Res"},{"key":"2022_CR35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","volume":"15","author":"F Mentre","year":"2015","unstructured":"Mentre F, Taburet AM, Guedj J, Anglaret X, Keita S, de Lamballerie X, Malvy D (2015) Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 15:150\u2013151","journal-title":"Lancet Infect Dis"},{"key":"2022_CR36","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko D, Laouenan C, Folkesson E, M\u2019Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P et al (2016) Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof of-concept trial in Guinea. PLoS Med 13:e1001967","journal-title":"PLoS Med"},{"key":"2022_CR37","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life threatening RNA virus infections. Pharmacol Ther 209:107512","journal-title":"Pharmacol Ther"},{"key":"2022_CR38","doi-asserted-by":"crossref","first-page":"e0006034","DOI":"10.1371\/journal.pntd.0006034","volume":"11","author":"P Chinello","year":"2017","unstructured":"Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E (2017) QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis 11:e0006034","journal-title":"PLoS Negl Trop Dis"},{"key":"2022_CR39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.5414\/CP202388","volume":"53","author":"Y Kumagai","year":"2015","unstructured":"Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, Oe T et al (2015) Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther 53:866\u2013874","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2022_CR40","doi-asserted-by":"crossref","unstructured":"Chen C, Zhang Y, Huang J, et al (2020) Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv 2020.03.17.20037432","DOI":"10.1101\/2020.03.17.20037432"},{"key":"2022_CR41","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E et al (2017) Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 60:1648\u20131661","journal-title":"J Med Chem"},{"key":"2022_CR42","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"2020","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020:101615","journal-title":"Travel Med Infect Dis"},{"key":"2022_CR43","unstructured":"World Health Organization (2018) WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Accessed 20 May 2020. https:\/\/www.who.int\/ebola\/drc-2018\/summaries-of-evidence experimentaltherapeutics.pdf"},{"key":"2022_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92:814\u2013818. https:\/\/doi.org\/10.1002\/jmv.25801","journal-title":"J Med Virol"},{"key":"2022_CR45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","volume":"18","author":"B Fu","year":"2020","unstructured":"Fu B, Xu X, Wei H (2020) Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 18:164","journal-title":"J Transl Med"},{"key":"2022_CR46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer F, Palese P (2015) Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167\u2013182","journal-title":"Nat Rev Drug Discov"},{"key":"2022_CR47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat F, Krammer F (2020) SARS-CoV-2 vaccines: status report. Immunity 52:583\u2013589","journal-title":"Immunity"},{"key":"2022_CR48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265\u2013269","journal-title":"Nature"},{"key":"2022_CR49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273","journal-title":"Nature"},{"key":"2022_CR50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727\u2013733","journal-title":"N Engl J Med"},{"key":"2022_CR51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X et al (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 581:215\u2013220","journal-title":"Nature."},{"key":"2022_CR52","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260\u20131263","journal-title":"Science"},{"key":"2022_CR53","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/jama.2020.2783","volume":"323","author":"L Lan","year":"2020","unstructured":"Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H (2020) Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 323:1502\u20131503","journal-title":"JAMA."},{"key":"2022_CR54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow KA, Parry HF, Sergeant M, Tyrrell DA (1990) The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 105:435\u2013446","journal-title":"Epidemiol Infect"},{"key":"2022_CR55","doi-asserted-by":"crossref","unstructured":"Jiang H-W, Li Y, Zhang H-N, et al (2020) Global profiling of SARS-CoV-2 specific IgG\/IgM responses of convalescents using a proteome microarray. medRxiv 2020: 2020.03.20.20039495","DOI":"10.1101\/2020.03.20.20039495"},{"key":"2022_CR56","doi-asserted-by":"crossref","unstructured":"Wu F, Wang A, Liu M, et al (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020: 2020.03.30.20047365","DOI":"10.2139\/ssrn.3566211"},{"key":"2022_CR57","unstructured":"https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus landscapencov.pdf?ua=1 (accessed on May 28th, 2020)"},{"key":"2022_CR58","doi-asserted-by":"publisher","unstructured":"Zhu FC, Li YH, Guan XH et al (2020, 2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open label, non-randomised, first-in-human trial. Lancet (London, England). https:\/\/doi.org\/10.1016\/S0140-6736(20)31208-3","DOI":"10.1016\/S0140-6736(20)31208-3"},{"key":"2022_CR59","doi-asserted-by":"publisher","unstructured":"Neumann-B\u00f6hme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schrey\u00f6gg J, Stargardt T (2020) Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 [published online ahead of print, 2020 Jun 26]. Eur J Health Econ:1\u20136. https:\/\/doi.org\/10.1007\/s10198-020-01208-6","DOI":"10.1007\/s10198-020-01208-6"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-02022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:22:43Z","timestamp":1626308563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-02022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-02022-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}